SK Plasma said that it had signed a contract to export 17.2 billion won ($14.2 million) worth of blood products with Aksia Health Care FZC.

Products for export included LIV-r Inj. and albumin.

Under the accord, Aksia will have the right to sell the product in Saudi Arabia, Kuwait, and the United Arab Emirates and supply blood products to the Saudi Arabian government.

The contract is the first since SK Plasma won the bid to supply blood products to the Singapore government in October.

The company attributed its success in the global market to its careful analysis of overseas markets for a long time and various global strategies.

SK Plasma also plans to actively target North African countries, such as Tunisia and Algeria, based on the recent achievements.

"Our strategy to provide various customized solutions, such as providing finished products, orders for processing, and export of technology, according to the situation and needs of each country has proved quite effective," SK Plasma CEO Kim Yun-ho said. "Based on the manufacturing technology and quality of blood products recognized through exports to Saudi Arabia and Singapore, we will step up effort to expand export markets."